Long-Term Outcomes in IgA Nephropathy

被引:131
|
作者
Pitcher, David [1 ,2 ]
Braddon, Fiona [1 ]
Hendry, Bruce [3 ]
Mercer, Alex [4 ]
Osmaston, Kate [1 ]
Saleem, Moin A. A. [5 ,6 ]
Steenkamp, Retha [1 ]
Wong, Katie [1 ,2 ]
Turner, A. Neil [7 ]
Wang, Kaijun [3 ]
Gale, Daniel P. P. [2 ]
Barratt, Jonathan [8 ,9 ,10 ]
机构
[1] UK Kidney Assoc, UK Renal Registry, Bristol, England
[2] UCL, Dept Renal Med, London, England
[3] Travere Therapeut Inc, San Diego, CA USA
[4] JAMCO Pharm Consulting, Stockholm, Sweden
[5] Univ Bristol, Bristol, England
[6] Bristol Royal Hosp Children, Bristol, England
[7] Univ Edinburgh, Edinburgh, Scotland
[8] Univ Leicester, Leicester, England
[9] Leicester Gen Hosp, Leicester, England
[10] Univ Leicester, Dept Cardiovasc Sci, Univ Rd, Leicester LE1 7RH, England
关键词
chronic kidney disease; chronic kidney failure; end-stage kidney disease (ESKD); end-stage renal disease (ESRD); IGA nephropathy; kidney disease; nephropathy; proteinuria; CHRONIC KIDNEY-DISEASE; URINE PROTEIN; ASSOCIATION; ALBUMINURIA; REMISSION; FAILURE; RISK;
D O I
10.2215/CJN.0000000000000135
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope, and lifetime risks for kidney failure. Methods The IgA nephropathy cohort (2299 adults and 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy plus proteinuria >0.5 g/d or eGFR <60 ml/min per 1.73 m(2). Incident and prevalent populations and a population representative of a typical phase 3 clinical trial cohort were studied. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. Results The median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. The median (95% confidence interval [CI]) kidney survival was 11.4 (10.5 to 12.5) years; the mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. On the basis of eGFR and age at diagnosis, almost all patients were at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss <= 1 ml/min per 1.73 m(2) per year was maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and clinical trial populations. Thirty percent of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the clinical trial population, each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87 to 0.92). Conclusions Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years.
引用
收藏
页码:727 / 738
页数:12
相关论文
共 50 条
  • [31] LONG-TERM FOLLOW-UP OF PATIENTS WITH IGA NEPHROPATHY
    BAILEY, RR
    LYNN, KL
    ROBSON, RA
    SMITH, AH
    WELLS, JE
    NEW ZEALAND MEDICAL JOURNAL, 1994, 107 (976) : 142 - 144
  • [32] COURSE AND LONG-TERM OUTCOME OF IDIOPATHIC IGA NEPHROPATHY IN CHILDREN
    LINNE, T
    BERG, U
    BOHMAN, SO
    SIGSTROM, L
    PEDIATRIC NEPHROLOGY, 1991, 5 (04) : 383 - 386
  • [33] Long-term outcome of childhood IgA nephropathy with minimal proteinuria
    Higa, Asumi
    Shima, Yuko
    Hama, Taketsugu
    Sato, Masashi
    Mukaiyama, Hironobu
    Togawa, Hiroko
    Tanaka, Ryojiro
    Nozu, Kandai
    Sako, Mayumi
    Iijima, Kazumoto
    Nakanishi, Koichi
    Yoshikawa, Norishige
    PEDIATRIC NEPHROLOGY, 2015, 30 (12) : 2121 - 2127
  • [34] Long-term prognosis of childhood IgA nephropathy in adult life
    Ariceta, G
    Gallego, N
    López-Fernández, Y
    Vallo, A
    Quintela, MJ
    Soriano, JR
    MEDICINA CLINICA, 2001, 116 (10): : 361 - 364
  • [35] LONG-TERM OUTCOME IN 145 PATIENTS WITH ASSUMED BENIGN IGA NEPHROPATHY
    Knoop, Thomas
    Vikse, Bjorn
    Mwakimonga, Angela
    Leh, Sabine
    Bjorneklett, Rune
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 83 - 83
  • [36] Long-term outcome of proteinuric IgA nephropathy treated with ACE inhibitors
    Gonzales, E
    Gutierrez, E
    Hernandez, E
    Morales, E
    Herrero, J
    Ortiz, M
    Praga, M
    Rodicio, J
    JOURNAL OF HYPERTENSION, 2002, 20 : S55 - S55
  • [37] Long-Term Results of a Randomized Controlled Trial in Childhood IgA Nephropathy
    Kamei, Koichi
    Nakanishi, Koichi
    Ito, Shuichi
    Saito, Mari
    Sako, Mayumi
    Ishikura, Kenji
    Hataya, Hiroshi
    Honda, Masataka
    Iijima, Kazumoto
    Yoshikawa, Norishige
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06): : 1301 - 1307
  • [38] The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy
    Xie, YS
    Nishi, S
    Ueno, M
    Imai, N
    Sakatsume, M
    Narita, I
    Suzuki, Y
    Akazawa, K
    Shimada, H
    Arakawa, M
    Gejyo, F
    KIDNEY INTERNATIONAL, 2003, 63 (05) : 1861 - 1867
  • [39] A clinicopathological study on the long-term efficacy of tonsillectomy in patients with IgA nephropathy
    Nishi, S
    Xie, YS
    Ueno, M
    Imai, N
    Suzuki, Y
    Iguchi, S
    Fukase, S
    Mori, H
    Alchi, B
    Shimada, H
    Arakawa, M
    Gejyo, F
    ACTA OTO-LARYNGOLOGICA, 2004, 124 : 49 - 53
  • [40] Childhood-onset IgA nephropathy: is long-term recovery possible?
    Antonucci, Luca
    Fuiano, Laura
    Gargiulo, Antonio
    Gianviti, Alessandra
    Muda, Andrea Onetti
    Camassei, Francesca Diomedi
    Vivarelli, Marina
    Emma, Francesco
    PEDIATRIC NEPHROLOGY, 2024, 39 (06) : 1837 - 1846